Member Info for Wellersworld

I’d add this is a speculative play right, there’s risk, BO. Is well within right to put his opinion out there.

Business owner mug 🤣

Bit rude but C’mon great use of language, seldom heard, funny, not overly offensive, gets across a clear sentiment.

While true there are lots of people with options, and larger shareholders, wouldn’t that be true of any stock, certainly in early stages.

Other tests developing yes, but this one is on verge of being live in US right now. There’s a potentially huge market about to open.

Work being done on NHS adoption, haven’t the expertise to suggest a time frame, but a successful roll out in US of a UK company must add some drive to NHS adoption.

Europe/ Asia no info presumably a long way off.

But still a lot to go here, if a could see real demand in next couple of months from US, potentially, wasn’t there national drive around cancer discussed in congress only a month or so ago?

Cr@opt to see SP fall, dis heartening for sure, I still see legs in this.

Hi all, . . . . . .-~. ~ @

Don’t much about the company yet, but really like the concept. Will try a little research but anyone out there know the market well or the company?

10:00 AS says about new markets, shareholders should “look out’ for that and coming soon. To me that sounds like watch this space. More confident in this than before, price is a bit of a let down though. Been a long play, now longer but seems positive, and might save thousands of lives.

Well said, could have been better comms, but I figure this is primarily a medical/research group not a business. Hope for good progress from here

One 2many. My only thought is why you asking advice here for that kind of commitment

HogBog that seem pretty achievable, Gl with that.

Been in this a long time, about where I first got in, have averaged down though. Always liked the project, if it does what it says on the tin, got to be a huge market.

I down tenfold on this, haven’t sold as I liked the concept, and the company really seemed to be getting it act together at one point, also US grants.

To sell and take massive loss, recoup pennies on the pounds or just leave it, consider total loss and keep it as a wild card.

Seems like a good post but, when was this posted? No context otherwise

If so might leave door open different reagents/ different tests. Interesting

Deffo has a Groundhog Day feeling 🤣

Larger trade today, crossing trade apparently. Just wondering if this is a n exchange, but it shows as as sell? Also I read this is a close of market trade, does it have ramifications when the market opens?

Probably a year ago there were a few posters on here that had some thought out price targets. Seems like we’re further forward, though share price is backwards 🤣. Any more astute people on here with ideas?

Do you think if you were a serious Vcapital firm, you’d make a play for a company reliant on a product by the parent group, seems to me the only sensible thing would be to aim for both. Never expected anything quick, but the fundamentals of the product seem good, long periods with little news/ progress. I guess that’s the Norm for a biotech

You’re a bit hostile man

Pretty sure I bought it, must have lost it down the back of the sofa. 🤔

I get people have done a lot of technical analysis, and there’s concern about competition, especially where there’s a NHS connection but, isnt a test for lung cancer such as CIZ is purported to be, made for the US market. I mean it’s the pretty much the spiritual home of smoking, not even much drive to reduce it. Also the way the health insurance industry is set up there, ‘pre’ ill -Health (ie. Routine) screening in the US makes a lot of sense, massive market.

If I was an insurer moral arguments aside, I’d be clamouring for a test that does what Ciz should do. I would have thought US market would dwarf NHS. Just putting a thought out there?

Was looking at this, seems to to not necessarily be a rival, more complementary. Say an early diagnosis via Ciz, follow up with QuicDna, to genetic identify the type, and targeted treatment.

“With the new QuicDNA program, patients will get a blood sample for ctDNA early in the diagnostic pathway when the lung physician suspects stage III or IV lung cancer. The genomic results will be available for the MDT meeting. Because more than 10 genetic biomarkers are associated with an approved therapy for lung cancer, genetic testing can significantly increase treatment options. “When you can identify, for example, an EGFR mutation through sequencing, a patient can potentially start oral therapy (tablets) the next day,” says Meissner.”

https://emea.illumina.com/company/news-center/feature-articles/a-liquid-biopsy-study-offers-new-hope-for-lung-cancer-patients.html

What’s these stupid 15 years olds messages-blocked